Blacksburg, Virginia – Living organisms often create what is needed for life from scratch. For humans, this process means the creation of most essential compounds needed to survive. But not every living thing has this capability, such as the parasite that causes malaria, which affected an estimated 249 million people...
Latest News
Blacksburg, VA – Cancer is the monster of our society. Last year alone, more than 600,000 people in the United States died from cancer, according to the American Cancer Society. The relentless pursuit of understanding this complex disease has shaped medical progress on developing treatment procedures that are less invasive...
Blacksburg, VA – For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is a big problem. Current standard treatments, including surgery, radiation, and chemotherapy using the drug temozolomide, have limited effectiveness and have not significantly changed in the past five decades. Although temozolomide can initially slow...
EXTON, Pa. — ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to its supplemental Biologics License Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of hereditary angioedema (HAE). The...
COLUMBIA, Mo. — Many people associate virtual reality headsets with interactive video games, but a researcher at the University of Missouri is using them for something far more important — helping autistic people navigate public transportation on college campuses. MU researcher Noah Glaser — in collaboration with Matthew Schmidt, an...
SHANGHAI, China — VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Administration (NMPA). Lonapegsomatropin is the first once-weekly administrated growth hormone approved by both the U.S. Food...
SOUTH SAN FRANCISCO, Calif. — Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued a Notice of Intention to Grant a patent related to the...
SAN MATEO, Calif. — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to VT3989 for the treatment of mesothelioma in the United States. VT3989, the company’s first-in-class...
SAN MATEO, Calif. — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to VT3989, the company’s first-in-class and best-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor....
In a touching turn of events, the Vodafone Ghana Foundation has made a profound impact on the life of Oleki Gaduga, a 12-year-old girl from Ada. Oleki was born with Infantile Blount Disease, a rare disorder that causes leg bowing and difficulty walking. Oleki had been suffering from severe pain...